JP7476174B2 - がんに対するa*01拘束性ペプチドおよびペプチド組み合わせによる免疫療法 - Google Patents

がんに対するa*01拘束性ペプチドおよびペプチド組み合わせによる免疫療法 Download PDF

Info

Publication number
JP7476174B2
JP7476174B2 JP2021514549A JP2021514549A JP7476174B2 JP 7476174 B2 JP7476174 B2 JP 7476174B2 JP 2021514549 A JP2021514549 A JP 2021514549A JP 2021514549 A JP2021514549 A JP 2021514549A JP 7476174 B2 JP7476174 B2 JP 7476174B2
Authority
JP
Japan
Prior art keywords
cancer
peptide
cells
cell
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021514549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502358A (ja
JP2022502358A5 (cg-RX-API-DMAC7.html
Inventor
シュスター,ハイコ
ゾンターク,アニカ
ダニエル,コバレフスキ
スホール,オリバー
フリッチェ,イェンス
ヴァインシェンク,トニ
シン,ハープリート
ソング,コレット
Original Assignee
イマティクス バイオテクノロジーズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68062920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7476174(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by イマティクス バイオテクノロジーズ ゲーエムベーハー filed Critical イマティクス バイオテクノロジーズ ゲーエムベーハー
Publication of JP2022502358A publication Critical patent/JP2022502358A/ja
Publication of JP2022502358A5 publication Critical patent/JP2022502358A5/ja
Priority to JP2024067065A priority Critical patent/JP2024102112A/ja
Application granted granted Critical
Publication of JP7476174B2 publication Critical patent/JP7476174B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021514549A 2018-09-18 2019-09-18 がんに対するa*01拘束性ペプチドおよびペプチド組み合わせによる免疫療法 Active JP7476174B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024067065A JP2024102112A (ja) 2018-09-18 2024-04-17 がんに対するa*01拘束性ペプチドおよびペプチド組み合わせによる免疫療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862732863P 2018-09-18 2018-09-18
DE102018122900 2018-09-18
DE102018122900.3 2018-09-18
US62/732,863 2018-09-18
PCT/EP2019/075065 WO2020058360A1 (en) 2018-09-18 2019-09-18 Immunotherapy with a*01 restricted peptides and combination of peptides against cancers and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024067065A Division JP2024102112A (ja) 2018-09-18 2024-04-17 がんに対するa*01拘束性ペプチドおよびペプチド組み合わせによる免疫療法

Publications (3)

Publication Number Publication Date
JP2022502358A JP2022502358A (ja) 2022-01-11
JP2022502358A5 JP2022502358A5 (cg-RX-API-DMAC7.html) 2023-06-16
JP7476174B2 true JP7476174B2 (ja) 2024-04-30

Family

ID=68062920

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021514549A Active JP7476174B2 (ja) 2018-09-18 2019-09-18 がんに対するa*01拘束性ペプチドおよびペプチド組み合わせによる免疫療法
JP2024067065A Pending JP2024102112A (ja) 2018-09-18 2024-04-17 がんに対するa*01拘束性ペプチドおよびペプチド組み合わせによる免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024067065A Pending JP2024102112A (ja) 2018-09-18 2024-04-17 がんに対するa*01拘束性ペプチドおよびペプチド組み合わせによる免疫療法

Country Status (19)

Country Link
US (10) US10954281B2 (cg-RX-API-DMAC7.html)
EP (1) EP3852787A1 (cg-RX-API-DMAC7.html)
JP (2) JP7476174B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210063320A (cg-RX-API-DMAC7.html)
CN (1) CN113164569A (cg-RX-API-DMAC7.html)
AU (1) AU2019342860A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021003511A2 (cg-RX-API-DMAC7.html)
CA (1) CA3108582A1 (cg-RX-API-DMAC7.html)
CL (3) CL2021000653A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021003404A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210141A (cg-RX-API-DMAC7.html)
IL (2) IL309715A (cg-RX-API-DMAC7.html)
MA (1) MA53644A (cg-RX-API-DMAC7.html)
MX (1) MX2021003089A (cg-RX-API-DMAC7.html)
PE (1) PE20211643A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550581A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101926TA (cg-RX-API-DMAC7.html)
TW (1) TW202024121A (cg-RX-API-DMAC7.html)
WO (1) WO2020058360A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201841934A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於治療癌症免疫治療的新穎肽及其肽組合物
CR20210160A (es) 2017-04-10 2021-04-26 Immatics Biotechnologies Gmbh Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer (divisional de solicitud 2019-0508)
WO2021188743A2 (en) * 2020-03-20 2021-09-23 Neo7Logix, Llc Precision-based immuno-molecular augmentation (pbima) computerized system, method and therapeutic vaccine
US12525329B2 (en) * 2020-03-20 2026-01-13 Neo7Bioscience, Inc. Precision-based immuno-molecular augmentation (PBIMA) computerized system, method, and therapeutic vaccine
JP7822953B2 (ja) * 2020-04-14 2026-03-03 ウニヴェルシテ ド モントリオール 急性骨髄性白血病(aml)に対する新規の腫瘍特異的抗原及びそれらの使用
CN115843747B (zh) * 2022-12-02 2024-08-20 吉林大学 一种Lama3基因点突变的小鼠模型及其构建方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017097699A1 (en) 2015-12-11 2017-06-15 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
WO2017202806A1 (en) 2016-05-25 2017-11-30 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP2018519243A (ja) 2015-03-27 2018-07-19 イマティクス バイオテクノロジーズ ゲーエムベーハー 様々な腫瘍に対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
YU44186B (en) 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US6805861B2 (en) 1996-01-17 2004-10-19 Imperial College Innovations Limited Immunotherapy using cytotoxic T lymphocytes (CTL)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1294748B1 (en) 2000-03-27 2010-06-30 Technion Research and Development of Foundation, Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP2322228B1 (en) 2000-06-05 2018-01-10 Altor BioScience Corporation T cell receptor fusion proteins and conjugates and methods of use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
EP2048159B1 (en) 2002-11-09 2014-01-01 Immunocore Ltd. T cell receptor display
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
DE602005020046D1 (de) 2005-09-05 2010-04-29 Immatics Biotechnologies Gmbh Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2632955A1 (en) 2010-10-26 2013-09-04 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
WO2014071978A1 (en) 2012-11-08 2014-05-15 Roche Diagnostics Gmbh Nucleic acids encoding chimeric polypeptides for library screening
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
CA3172682A1 (en) 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201520559D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
US11175289B2 (en) * 2016-11-16 2021-11-16 Lei Han Application of TRPM8 protein, related peptide fragment and their antibodies
JP7722629B2 (ja) 2017-07-04 2025-08-13 キュアバック エスイー 新規核酸分子

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018519243A (ja) 2015-03-27 2018-07-19 イマティクス バイオテクノロジーズ ゲーエムベーハー 様々な腫瘍に対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ
WO2017097699A1 (en) 2015-12-11 2017-06-15 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
WO2017202806A1 (en) 2016-05-25 2017-11-30 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
YEE, Nelson S.,Cancers,2015年10月23日,Vol. 7, No. 4,pp. 2134-2146,DOI: 10.3990/cancers7040882
がん免疫療法のメカニズム解明と臨床への展開 がんと免疫,1版,2015年,p. 176-185

Also Published As

Publication number Publication date
US20200087364A1 (en) 2020-03-19
MA53644A (fr) 2021-07-28
CL2021000653A1 (es) 2021-08-20
WO2020058360A1 (en) 2020-03-26
CL2023000659A1 (es) 2023-08-18
US20220002366A1 (en) 2022-01-06
TW202024121A (zh) 2020-07-01
US20200325199A1 (en) 2020-10-15
US20200325198A1 (en) 2020-10-15
US12195506B2 (en) 2025-01-14
US20200325197A1 (en) 2020-10-15
CO2021003404A2 (es) 2021-04-08
US10954281B2 (en) 2021-03-23
CL2023000658A1 (es) 2023-08-18
CN113164569A (zh) 2021-07-23
JP2022502358A (ja) 2022-01-11
US12060399B2 (en) 2024-08-13
US20220009982A1 (en) 2022-01-13
MX2021003089A (es) 2021-05-12
US20200325196A1 (en) 2020-10-15
US10899814B2 (en) 2021-01-26
US20210238243A1 (en) 2021-08-05
CR20210141A (es) 2021-06-10
SG11202101926TA (en) 2021-04-29
PE20211643A1 (es) 2021-08-24
US10899813B2 (en) 2021-01-26
IL281596A (en) 2021-05-31
PH12021550581A1 (en) 2021-11-29
US20200325195A1 (en) 2020-10-15
US11001617B2 (en) 2021-05-11
AU2019342860A1 (en) 2021-03-04
IL309715A (en) 2024-02-01
US10870685B2 (en) 2020-12-22
US10899812B2 (en) 2021-01-26
KR20210063320A (ko) 2021-06-01
US11142556B2 (en) 2021-10-12
EP3852787A1 (en) 2021-07-28
BR112021003511A2 (pt) 2021-05-18
US20250092104A1 (en) 2025-03-20
CA3108582A1 (en) 2020-03-26
JP2024102112A (ja) 2024-07-30

Similar Documents

Publication Publication Date Title
JP7732024B2 (ja) 異なるタイプのがんに対する免疫療法で使用するための非標準起源のペプチドおよびペプチド組み合わせ
JP2023093483A (ja) 子宮がん治療法
JP2025038025A (ja) 前立腺がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
JP7476165B2 (ja) がんに対するb*07拘束性ペプチドおよびペプチド組み合わせによる免疫療法
US20230002462A1 (en) B*44 restricted peptides for use in immunotherapy against cancers and related methods
JP7579145B2 (ja) がんに対する免疫療法で使用するためのa*03拘束性ペプチドおよび関連方法
JP2025038026A (ja) Nsclc、sclc、およびその他のがんをはじめとする肺がんに対する免疫療法で使用するための新規ペプチドおよびペプチド併用
US12060400B2 (en) Peptides for use in immunotherapy against cancers
JP2024102112A (ja) がんに対するa*01拘束性ペプチドおよびペプチド組み合わせによる免疫療法
JP7564183B2 (ja) 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤
US20250145684A1 (en) Immunotherapy with b*08 restricted peptides and combination of peptides against cancers and related methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240417

R150 Certificate of patent or registration of utility model

Ref document number: 7476174

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150